Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

Pfizer Inc. will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology Annual Meeting, taking place May 30 to June 3 in ...

Pfizer Inc. (NYSE:PFE) Analyst and Investor Call to Review Oncology Business and ASCO Data Presentations Call June 8, 2016 10:00 AM ETExecutivesChuck Triano ...

Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a higher ...

Pfizer PFE 0.74 % increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.